FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205511886> ?p ?o ?g. }

• W4205511886 abstract "Abstract Objectives: Significant knowledge gaps exist regarding the comorbidities, treatment and lab testing patterns of patients with chronic hypoparathyroidism (cHP). This study describes a large cohort of patients with cHP identified using a diagnosis-based criteria from a claims database. Methods: This retrospective cohort study was conducted using a large (130 million individuals) claims database (HealthVerity Closed Payer Claim Medical and Pharmacy databases: Private Source 20) from Oct 2014 to Dec 2019. Eligible patients had ≥2 diagnosis claims of HP (ICD9/10 codes: E20.0, E20.8, E20.9, 252.1) that were 6–15 months apart, a prescription claim for either active vitamin D, calcium, PTH or thyroid replacement therapy between the first qualifying HP claim and within 30 days of the second HP claim, and continuous enrollment for one year before the index date (the date of the first of two qualifying HP diagnosis claims) and ≥16 months after. Patients were followed up to two years after the index date. Patient characteristics, comorbidities, lab testing and treatment patterns were descriptively analyzed. Results: Out of 43,640 patients with a diagnosis claim for HP, 4,118 patients met the eligibility criteria. The mean age of the cohort was 56.5 years + 18.6 (SD), and 76.4% were females, similar to data from other large cohort studies. The most common comorbidities during the 1-year follow-up were hypertension (56.0%), hypocalcemia (38.7%), cancer (30.5%, of which 24% were thyroid cancers), diabetes (29.4%), chronic pulmonary disease (24.1%), cardiac arrhythmias (17.4%), CKD stage 3–5 (17.0%), osteoporosis (9.6%) and neuropsychiatric disorders, including depressive disorders (22.0%), anxiety (21.6%), and sleep-wake disorders (18.4%). During the 1-year follow up, commonly monitored lab tests included serum calcium (89.9%), eGFR/creatinine (85.7%), 25-hydroxy vitamin D (61.1%), and intact PTH (43.9%). Remarkably, serum phosphorous (36.3%), serum magnesium (35.4%), and 24h-urine calcium (10.5%) were much less often monitored. In addition, BMD was measured in 10.9% patients. Also during the 1-year follow-up, 67.1% of patients had a prescription claim for thyroid replacement therapy, 60.5% for calcitriol, 15.7% for ergocalciferol, and 3.4 % for PTH. Conclusion: Findings from this study highlight the high comorbidity burden in cHP patients which aligns with the monitoring patterns. Kidney function appears to be a key concern and may be important when considering therapeutic intervention. The comorbidities and practice patterns observed in this study are consistent with the results obtained using a surgery-based approach to identify cHP patients in the same claims database. Future studies will also examine the economic burden of cHP." @default.
• W4205511886 created "2022-01-26" @default.
• W4205511886 creator A5020992397 @default.
• W4205511886 creator A5030588384 @default.
• W4205511886 creator A5031937268 @default.
• W4205511886 creator A5041242049 @default.
• W4205511886 creator A5043155453 @default.
• W4205511886 creator A5057116898 @default.
• W4205511886 creator A5057378595 @default.
• W4205511886 creator A5083042599 @default.
• W4205511886 creator A5089760217 @default.
• W4205511886 date "2021-05-01" @default.
• W4205511886 modified "2023-10-16" @default.
• W4205511886 title "Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis-Based Criteria" @default.
• W4205511886 doi "https://doi.org/10.1210/jendso/bvab048.526" @default.
• W4205511886 hasPublicationYear "2021" @default.
• W4205511886 type Work @default.
• W4205511886 citedByCount "0" @default.
• W4205511886 crossrefType "journal-article" @default.
• W4205511886 hasAuthorship W4205511886A5020992397 @default.
• W4205511886 hasAuthorship W4205511886A5030588384 @default.
• W4205511886 hasAuthorship W4205511886A5031937268 @default.
• W4205511886 hasAuthorship W4205511886A5041242049 @default.
• W4205511886 hasAuthorship W4205511886A5043155453 @default.
• W4205511886 hasAuthorship W4205511886A5057116898 @default.
• W4205511886 hasAuthorship W4205511886A5057378595 @default.
• W4205511886 hasAuthorship W4205511886A5083042599 @default.
• W4205511886 hasAuthorship W4205511886A5089760217 @default.
• W4205511886 hasBestOaLocation W42055118861 @default.
• W4205511886 hasConcept C104863432 @default.
• W4205511886 hasConcept C121608353 @default.
• W4205511886 hasConcept C126322002 @default.
• W4205511886 hasConcept C134018914 @default.
• W4205511886 hasConcept C167135981 @default.
• W4205511886 hasConcept C187212893 @default.
• W4205511886 hasConcept C2426938 @default.
• W4205511886 hasConcept C2775941721 @default.
• W4205511886 hasConcept C2779761222 @default.
• W4205511886 hasConcept C2780176905 @default.
• W4205511886 hasConcept C512399662 @default.
• W4205511886 hasConcept C526584372 @default.
• W4205511886 hasConcept C555293320 @default.
• W4205511886 hasConcept C71924100 @default.
• W4205511886 hasConcept C72563966 @default.
• W4205511886 hasConcept C98274493 @default.
• W4205511886 hasConceptScore W4205511886C104863432 @default.
• W4205511886 hasConceptScore W4205511886C121608353 @default.
• W4205511886 hasConceptScore W4205511886C126322002 @default.
• W4205511886 hasConceptScore W4205511886C134018914 @default.
• W4205511886 hasConceptScore W4205511886C167135981 @default.
• W4205511886 hasConceptScore W4205511886C187212893 @default.
• W4205511886 hasConceptScore W4205511886C2426938 @default.
• W4205511886 hasConceptScore W4205511886C2775941721 @default.
• W4205511886 hasConceptScore W4205511886C2779761222 @default.
• W4205511886 hasConceptScore W4205511886C2780176905 @default.
• W4205511886 hasConceptScore W4205511886C512399662 @default.
• W4205511886 hasConceptScore W4205511886C526584372 @default.
• W4205511886 hasConceptScore W4205511886C555293320 @default.
• W4205511886 hasConceptScore W4205511886C71924100 @default.
• W4205511886 hasConceptScore W4205511886C72563966 @default.
• W4205511886 hasConceptScore W4205511886C98274493 @default.
• W4205511886 hasLocation W42055118861 @default.
• W4205511886 hasOpenAccess W4205511886 @default.
• W4205511886 hasPrimaryLocation W42055118861 @default.
• W4205511886 hasRelatedWork W11272637 @default.
• W4205511886 hasRelatedWork W14963511 @default.
• W4205511886 hasRelatedWork W15338904 @default.
• W4205511886 hasRelatedWork W17696275 @default.
• W4205511886 hasRelatedWork W4560225 @default.
• W4205511886 hasRelatedWork W6986156 @default.
• W4205511886 hasRelatedWork W777628 @default.
• W4205511886 hasRelatedWork W7953823 @default.
• W4205511886 hasRelatedWork W8808446 @default.
• W4205511886 hasRelatedWork W9764376 @default.
• W4205511886 isParatext "false" @default.
• W4205511886 isRetracted "false" @default.
• W4205511886 workType "article" @default.